Achieve Life Sciences, Inc. (NASDAQ:ACHV) Short Interest Down 9.6% in November

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) was the recipient of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 3,000,000 shares, a decline of 9.6% from the October 31st total of 3,320,000 shares. Based on an average trading volume of 107,500 shares, the short-interest ratio is presently 27.9 days.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ACHV shares. Oppenheimer restated an "outperform" rating and issued a $11.00 target price on shares of Achieve Life Sciences in a research note on Thursday, August 15th. RODMAN&RENSHAW upgraded shares of Achieve Life Sciences to a "strong-buy" rating in a research note on Thursday, November 14th. Raymond James began coverage on shares of Achieve Life Sciences in a research report on Friday, September 27th. They set a "strong-buy" rating and a $20.00 target price on the stock. Finally, Rodman & Renshaw assumed coverage on shares of Achieve Life Sciences in a research note on Thursday, November 14th. They issued a "buy" rating and a $12.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Achieve Life Sciences has a consensus rating of "Buy" and a consensus target price of $14.80.

Achieve Life Sciences Price Performance

Shares of NASDAQ:ACHV traded down $0.08 on Friday, hitting $4.41. The stock had a trading volume of 44,848 shares, compared to its average volume of 124,126. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78. The firm's 50 day moving average price is $4.71 and its 200-day moving average price is $4.74. The company has a market capitalization of $151.66 million, a price-to-earnings ratio of -3.90 and a beta of 1.57. Achieve Life Sciences has a twelve month low of $3.03 and a twelve month high of $5.96.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.10). During the same quarter in the prior year, the company earned ($0.34) EPS. On average, equities research analysts predict that Achieve Life Sciences will post -1.17 earnings per share for the current year.

Institutional Investors Weigh In On Achieve Life Sciences

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Achieve Life Sciences by 56.6% in the first quarter. Vanguard Group Inc. now owns 948,441 shares of the biopharmaceutical company's stock valued at $4,311,000 after purchasing an additional 342,731 shares during the period. Geode Capital Management LLC raised its holdings in Achieve Life Sciences by 6.9% in the 3rd quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company's stock valued at $3,552,000 after acquiring an additional 48,474 shares during the period. State Street Corp lifted its position in Achieve Life Sciences by 6.8% during the third quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company's stock worth $2,045,000 after acquiring an additional 27,419 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Achieve Life Sciences during the second quarter worth approximately $482,000. Finally, Barclays PLC boosted its holdings in shares of Achieve Life Sciences by 303.1% during the third quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company's stock worth $226,000 after acquiring an additional 35,832 shares during the period. Institutional investors own 33.52% of the company's stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.